Policy & Regulation
-
Douglas Cliff via Getty Images
FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage
After initially declaring the shortage of Eli Lilly’s diabetes and weight loss drugs over, the FDA changed its mind and re-opened the door for GLP-1 compounders.
By Amy Baxter • Oct. 21, 2024 -
Win McNamee via Getty Images
As election day nears, Trump and Harris veer in different directions on pharma
The two presidential candidates have developed diverging policies related to healthcare and pharma.
By Amy Baxter • Oct. 14, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Permission granted by DeepWell
Will a Medicare boost propel digital therapeutics to the mainstream?
Digital therapeutics have languished in the background of traditional medicines for years, but a recent reimbursement push may have gotten the ball rolling.
By Kelly Bilodeau • Oct. 14, 2024 -
Stock via Getty Images
BMS’ next act for Cobenfy — and other highs and lows in Alzheimer’s
The Alzheimer’s space is booming, from a new use for a schizophrenia drug to discovered pathways linked to the disease — but there’s been stumbles too.
By Meagan Parrish • Oct. 11, 2024 -
Courtesy of Madrigal
How Madrigal plans to win on the market with the first MASH drug
Despite the drug’s wide patient pool, Madrigal is taking a targeted approach with its first launch.
By Amy Baxter • Oct. 10, 2024 -
Permission granted by Katelyn Jetelina
Q&A‘It’s been hard to watch.’ A noted epidemiologist talks H5N1 and the U.S.’s fragmented response.
Katelyn Jetelina, well known for her newsletter “Your Local Epidemiologist,” digs into the H5N1 outbreak, the public health response and what’s next for vaccinations.
By Alexandra Pecci • Oct. 9, 2024 -
Stock via Getty Images
An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped?
Cassava Sciences’ beleaguered investigational Alzheimer’s therapy is in two phase 3 studies.
By Meagan Parrish • Oct. 4, 2024 -
Mario Tama / Getty via Getty Images
Flu vaccination rates are falling despite record child deaths. Can innovation save the day?
As respiratory disease season approaches, experts are concerned about vaccination rates — but the industry is churning out new solutions to help.
By Michael Gibney • Oct. 3, 2024 -
Stock via Getty Images
Behind the rise of BMS’ Cobenfy, the first new schizophrenia drug in decades
The FDA OK for KarXT, now known as Cobenfy, demonstrates Bristol Myers Squibb’s dealmaking prowess and marks a turning point for a new generation of treatments.
By Kelly Bilodeau • Sept. 26, 2024 -
Anna Moneymaker via Getty Images
What the Fed’s rate cut means for biotech
Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.
By Ben Fidler • Sept. 20, 2024 -
Sarah Silbiger via Getty Images
Getting IND ready — how companies can avoid common traps
Overpromising, overcommitting and neglecting CMC are a few of the pitfalls that cause sponsors to stumble when submitting a new drug application.
By Alexandra Pecci • Sept. 18, 2024 -
Stock via Getty Images
FDA inspection backlog overseas threatens new drug approvals
The FDA’s backlog of overseas drug manufacturer inspections is still mounting — and new drugs could be delayed as a result.
By Amy Baxter • Sept. 18, 2024 -
Win McNamee via Getty Images
Biopharma prepares to pivot from China as Biosecure Act advances
After the House of Representatives passed the Biosecure Act last week, U.S. biotechs could be forced to cut ties with five Chinese contract partners.
By Amy Baxter • Sept. 16, 2024 -
Michael Vi / Getty Images via Getty Images
Q&AHow Lilly’s sustainability goals come face to face with massive growth
Eli Lilly’s head of ESG is maintaining a focus on sustainability even as the company’s expansion plans in weight loss drive a larger footprint and more social scrutiny.
By Michael Gibney • Sept. 12, 2024 -
Getty Images via Getty Images
A new way of determining a drug’s value — with health equity in mind
Quality-adjusted life years are an important tool to frame a drug’s cost effectiveness, but they leave out other determinants of health.
By Michael Gibney • Sept. 10, 2024 -
Stock via Getty Images
What 3 layoff stories reveal about pharma’s troubles
The factors driving the industry’s layoffs — and what could help turn the tide.
By Meagan Parrish • Sept. 6, 2024 -
Sarah Silbiger via Getty Images
FDA adcomm reform talks heat up
As the agency considers eliminating adcomm votes from the approval process, members vie to have their voices heard.
By Amy Baxter • Sept. 3, 2024 -
Stock via Getty Images
After an FDA rejection, here’s what’s next in the psychedelics pipeline
By rejecting the first MDMA therapy earlier this month, the FDA signaled to the psychedelic drug sector that the road to approval isn’t clear cut.
By Amy Baxter • Aug. 28, 2024 -
PierreDesrosiers via Getty Images
Pharmas’ IRA court losses mount. They keep pursuing them.
The final drug prices for Medicare’s negotiation program have been published, but pharma companies continue to push their legal strategies.
By Amy Baxter • Aug. 26, 2024 -
Getty Images via Getty Images
Will the IRA squash new drugs? Those worries are likely exaggerated, studies say.
There’s no link between revenue and R&D from smaller biotechs, and that’s where most innovation comes from, according to new studies.
By Alexandra Pecci • Aug. 22, 2024 -
Drew Angerer via Getty Images
Pharma’s concerns pile up months after Supreme Court’s landmark Chevron decision
The Supreme Court case added another layer of uncertainty on the regulatory front and opened up the Inflation Reduction Act to more legal attacks.
By Amy Baxter • Aug. 21, 2024 -
Kena Betancur via Getty Images
The drugs hit hardest by Medicare price negotiations
The final negotiations slash drug prices between 38% and 79% for Medicare’s 2026 calendar year.
By Amy Baxter • Aug. 16, 2024 -
Scott Olson via Getty Images
Medicare reveals results of drug price negotiations
The agency said the first round of pricing talks, which involved drugs like the blood thinners Eliquis and Xarelto, will result in $6 billion in savings for taxpayers.
By Ned Pagliarulo • Aug. 15, 2024 -
Permission granted by Reed Tuckson
Lessons from COVID: Tuskegee impacts still erode trust in healthcare, but hope shines through
A long-time leader in public health and outreach to people of color, Dr. Reed Tuckson offers the lessons he learned from the COVID pandemic and how pharma can better serve those communities.
By Michael Gibney • Aug. 15, 2024 -
Permission granted by Moderna
Pfizer, GSK and Moderna execs remain optimistic about RSV vaccines despite CDC blowback
An advisory committee’s age group recommendations look like a major setback, but executives are painting a rosier picture.
By Michael Gibney • Aug. 6, 2024
